Three different ICIs, PD‐1 inhibitors, PD‐L1 inhibitors, and CTLA‐4 inhibitors, have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of various cancer types.15 This evidence concerns the gene PDCD1 and cancer.